- Home
- BYSI vs CNTX Comparison
BYSI vs CNTX Comparison
Compare BYSI & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BYSI
- CNTX
- Stock Information
- Founded
- BYSI 2010
- CNTX 2015
- Country
- BYSI United States
- CNTX United States
- Employees
- BYSI N/A
- CNTX N/A
- Industry
- BYSI Biotechnology: Pharmaceutical Preparations
- CNTX Biotechnology: Pharmaceutical Preparations
- Sector
- BYSI Health Care
- CNTX Health Care
- Exchange
- BYSI Nasdaq
- CNTX Nasdaq
- Market Cap
- BYSI 72.1M
- CNTX 60.7M
- IPO Year
- BYSI 2017
- CNTX 2021
- Fundamental
- Price
- BYSI $1.31
- CNTX $0.84
- Analyst Decision
- BYSI
- CNTX Strong Buy
- Analyst Count
- BYSI 0
- CNTX 5
- Target Price
- BYSI N/A
- CNTX $6.50
- AVG Volume (30 Days)
- BYSI 24.5K
- CNTX 257.9K
- Earning Date
- BYSI 01-01-0001
- CNTX 05-07-2025
- Dividend Yield
- BYSI N/A
- CNTX N/A
- EPS Growth
- BYSI N/A
- CNTX N/A
- EPS
- BYSI N/A
- CNTX N/A
- Revenue
- BYSI N/A
- CNTX N/A
- Revenue This Year
- BYSI N/A
- CNTX N/A
- Revenue Next Year
- BYSI N/A
- CNTX N/A
- P/E Ratio
- BYSI N/A
- CNTX N/A
- Revenue Growth
- BYSI N/A
- CNTX N/A
- 52 Week Low
- BYSI $0.98
- CNTX $0.55
- 52 Week High
- BYSI $3.63
- CNTX $2.75
- Technical
- Relative Strength Index (RSI)
- BYSI 44.17
- CNTX 56.99
- Support Level
- BYSI $1.03
- CNTX $0.80
- Resistance Level
- BYSI $1.27
- CNTX $0.89
- Average True Range (ATR)
- BYSI 0.15
- CNTX 0.11
- MACD
- BYSI 0.00
- CNTX 0.03
- Stochastic Oscillator
- BYSI 48.53
- CNTX 73.80
About BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It has two reportable segments Plinabulin pipeline and the TPD platform.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 ("CLDN6") x anti-CD3 bispecific antibody ("bsAb") that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.